Key facts
- This page summarizes Grant C. Bogle's Form 4 filing for Epizyme, Inc..
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Aug 2022, 21:00.
Grant C. Bogle - 09 Aug 2022 Form 4 Insider Report for Epizyme, Inc.
- Reporting relationship
- President and Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 09 Aug 2022
- Net transaction value
- +$106,241
- SEC form
- 4
- Accepted by SEC
- 11 Aug 2022, 21:00:55 UTC
- Prior SEC filing
- 21 Mar 2022
- Next SEC filing
- 16 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Weidenbruch, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Grant C. Bogle filed Form 4 for Epizyme, Inc. on 11 Aug 2022.
Change
- Previous filing in this sequence was filed on 21 Mar 2022.
- Current net transaction value: +$106,241.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EPZM
transaction
Common Stock, par value $0.0001
Options Exercise
- Transaction value
- $1,112,000
- Shares
- +800,000
- Change %
- +437%
- Price
- $1.39
- Shares after
- 983,060
- Date
- 09 Aug 2022
- Ownership
- Direct
EPZM
transaction
Common Stock, par value $0.0001
Tax liability
- Transaction value
- $1,037,367
- Shares
- -746,307
- Change %
- -76%
- Price
- $1.39
- Shares after
- 236,753
- Date
- 09 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
EPZM
transaction
Common Stock, par value $0.0001
Options Exercise
- Transaction value
- $588,675
- Shares
- +417,500
- Change %
- +176%
- Price
- $1.41
- Shares after
- 654,253
- Date
- 09 Aug 2022
- Ownership
- Direct
EPZM
transaction
Common Stock, par value $0.0001
Tax liability
- Transaction value
- $557,067
- Shares
- -395,083
- Change %
- -60%
- Price
- $1.41
- Shares after
- 259,170
- Date
- 09 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EPZM
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -800,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 800,000
- Exercise price
- $1.39
- Footnotes
- F2
EPZM
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -417,500
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 417,500
- Exercise price
- $1.41
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 9, 2022.
Footnote F2
On June 27, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. Pursuant to the terms of the Merger Agreement, each Exercisable Pre-Close Option (as defined in the Merger Agreement) became exercisable on the Acceleration Date (August 5, 2022) up to and through the close of regular trading on the Nasdaq Stock Market on the second (2nd) business day thereafter (August 9, 2022).
SEC remarks
President and Chief Executive Officer